PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 26, 2026Cochrane library0 citations

Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B

View Full Paper
OOOmotola O OlasupoNNNoella NoronhaMLMegan S Lowe

Key Points

  • The aim is to evaluate the effectiveness of non-clotting factor therapies in preventing bleeding episodes in individuals with congenital hemophilia A or B.
  • Conducted randomized controlled trials (RCTs) comparing non-clotting factor therapies to on-demand treatment.
  • Assessed frequency of bleeding events and percentage of individuals with zero bleeds.
  • Evaluated non-serious adverse events and health-related quality of life (HRQoL).
  • Non-clotting factor therapies reduced the overall bleeding events compared to on-demand treatments.
  • There was an increased percentage of individuals experiencing zero bleeds.
  • The incidence of non-serious adverse events increased among those receiving non-clotting factor therapies.

Abstract

Evidence from RCTs shows that prophylaxis using non-clotting factor therapies compared with on-demand treatment may reduce bleeding events, increase the percentage of individuals with zero bleeds, increase the incidence of non-serious adverse events, and improve HRQoL. Comparative assessments with other prophylaxis regimens, assessment of long-term joint outcomes, and assessment of economic outcomes will improve evidence-based decision-making for the use of these therapies in bleed prevention.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Olasupo et al. (2026) studied this question.

synapsesocial.com/papers/69c4cda5fdc3bde44891a53ahttps://doi.org/10.1002/14651858.cd014544.pub3
Ask AI
Helpful
Bookmark
Share
View Full Paper